BACKGROUND: Partial prostate treatment has emerged as a potential method for treating patients with favorable-risk prostate cancer while minimizing toxicity. The authors previously demonstrated poor rates of biochemical disease control for patients with National Comprehensive Cancer Network (NCCN) intermediate-risk disease using partial gland treatment with brachytherapy. The objective of the current study was to estimate the rates of distant metastasis and prostate cancer-specific mortality (PCSM) for this cohort. METHODS: Between 1997 and 2007, a total of 354 men with clinical T1c disease, a prostate-specific antigen (PSA) level < 15 ng/mL, and Gleason grade 3 1 4 prostate cancer underwent partial prostate treatment with brachytherapy to the peripheral zone under 0.5-Tesla magnetic resonance guidance. The cumulative incidences of metastasis and PCSM for the NCCN very low-risk, low-risk, and intermediate-risk groups were estimated. Fine and Gray competing risk regression was used to evaluate clinical factors associated with time to metastasis. RESULTS: A total of 22 patients developed metastases at a median of 11.0 years (interquartile range, 6.9-13.9 years). The 12-year metastasis rates for patients with very low-risk, low-risk, and intermediate-risk disease were 0.8% (95% confidence interval [95% CI], 0.1%-4.4%), 8.7% (95% CI, 3.4%-17.2%), and 15.7% (95% CI, 5.7%-30.2%), respectively, and the 12-year PCSM estimates were 1.6% (95% CI, 0.1%-7.6%), 1.4% (95% CI, 0.1%-6.8%), and 8.2% (95% CI, 1.9%-20.7%), respectively. 
INTRODUCTION
Low-dose rate prostate brachytherapy involves the insertion of radioactive seeds into the prostate gland. 1 Brachytherapy monotherapy can yield excellent outcomes for patients with National Comprehensive Cancer Network (NCCN) lowrisk, intermediate-risk, and even high-risk disease. [2] [3] [4] [5] [6] NCCN guidelines include brachytherapy as monotherapy for patients with low-risk and low-volume intermediate-risk disease. Furthermore, brachytherapy is included as an optional boost after external beam radiotherapy (EBRT) for patients with intermediate-risk and high-risk disease. 7 In the contemporary era, the entire prostate is implanted during the brachytherapy procedure. Studies have shown that dosimetric undercoverage of the prostate gland is associated with an increased risk of biochemical disease recurrence. 2, 8 However, ensuring dosimetric coverage of the entire prostate gland can be challenging, especially given the close proximity of critical structures, including the urethra, neurovascular bundles, and the rectum. Exceeding commonly accepted dose constraints for certain structures may place the patient at high risk of clinically significant urinary or rectal toxicities. 1, 9 A potential method for reducing radiation toxicity is to perform a partial implant. The peripheral zone of the prostate is the region at greatest risk of harboring prostate cancer, 10, 11 and therefore implanting this region alone could spare the urethra from the radiation dose and reduce genitourinary toxicity. Although ultrasound imaging does not provide a clear delineation of intraprostatic zonal anatomy, magnetic resonance imaging (MRI) can provide a clear delineation of the peripheral versus central/transitional zones. 12 Current multiparametric MRI techniques with Prostate Imaging Reporting and Data System (PI-RADS; version 2.0) also can assist in the accurate detection and localization of clinically significant prostate cancer. 13, 14 However, to the best of our knowledge, it is not known whether partial prostate radiation can provide the same long-term disease control as treatment of the entire gland.
Our group has extensive experience with MRIguided interstitial prostate brachytherapy, in which radioactive seeds are implanted under direct in-bore 0.5-Tesla MR guidance into the peripheral zone of the prostate in men with favorable-risk disease. 15 We previously have shown that partial prostate brachytherapy provided suboptimal biochemical disease control for patients with intermediate-risk disease. 16 The objective of the current study was to estimate the rates of distant metastasis and prostate cancer-specific mortality (PCSM) for patients with intermediate-risk disease.
MATERIALS AND METHODS

Treatment Characteristics
All procedures were performed after approval by an institutional review board or ethics committee and in accordance with an assurance filed with and approved by the US Department of Health and Human Services. A retrospective review of all men who underwent MRI-guided partial prostate brachytherapy from 1997 through 2007 was conducted. Patients selected for this therapy had clinical T1c, Gleason grade 3 1 3 or 3 1 4 disease, and a prostate-specific antigen (PSA) level < 15 ng/mL. All patients also underwent an endorectal MRI at 1.5 Tesla before the implantation. None of these patients had current multiparametric MRI with PI-RADS interpretations.
The prostate implantation was performed in an interventional suite using a Signa SP 0.5-Tesla interventional MRI scanner (General Electric Medical Systems, Milwaukee, Wisconsin). The peripheral zone was delineated as the target volume for implantation. The urethra and anterior rectal wall were contoured as avoidance structures. A treatment plan then was created, such that the minimum peripheral target dose was 137 Gray (Gy). Iodine-125 seeds (model 6711; Nycomed Amersham, Arlington Heights, Illinois) were implanted into the prostate using an MRI-compatible template with a peripheral loading technique. Real-time dosimetry was performed with iterative MRI scans. 15 Select patients who had a PSA level between 10.1 and 14.9 ng/mL, > 50% positive biopsy cores, or MRI evidence of extracapsular extension received EBRT (45 Gy in 25 fractions) to the prostate and seminal vesicles followed by a brachytherapy boost (90 Gy).
Patients were followed with a digital rectal examination and PSA level every 3 months for 2 years, and every 6 months thereafter. A subset of patients with a significant PSA increase underwent repeat endorectal MRI and/or biopsy to detect a local disease recurrence. Patients with persistently rising PSA underwent staging scans (eg, bone scan or computed tomography scans of the abdomen/pelvis) and salvage therapies (eg, androgen deprivation therapy [ADT], salvage brachytherapy, or salvage prostatectomy) at the discretion of the treating physician.
Failure Definitions
Two definitions of biochemical disease failure were evaluated. The first was the standard nadir plus 2 definition based on the Phoenix criteria. 17 All patients who met this criteria, including those with a subsequent PSA decline indicative of a bounce, were included given uncertainty in PSA kinetics after partial gland treatment with residual PSA-producing gland. The second was a modified definition that incorporated the nadir plus 2 definition along with a PSA velocity 0.75 ng/mL per year between the nadir and the value before salvage treatment. 16 Local disease recurrence was defined as biopsyproven disease within the prostate gland after the implantation. Metastasis was defined as the spread of disease outside of the prostate gland, as confirmed by imaging. PCSM was defined as death secondary to prostate cancer metastasis.
Statistical Analysis
Kaplan-Meier analysis was performed to estimate biochemical disease recurrence based on the standard and modified definitions. The log-rank test was used to compare survival curves.
Cumulative incidence curves were estimated for biopsy-proven local disease recurrence, ADT, metastasis, and PCSM, with deaths from non-prostate cancer causes as a competing risk. The kappa sample test was used to compare cumulative incidence curves. Fine and Gray competing risk regression was used to evaluate clinical factors associated with times to metastasis. Factors found to be statistically significant (P<.05) on univariate analyses were included in multivariate analyses. All statistical analyses were performed with R statistical software (version 3.0.2; The R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Between 1997 and 2007, a total of 354 men underwent MRI-guided partial prostate brachytherapy. Table 1 shows relevant clinical and treatment-related information. The numbers of patients with <6, 6 to 12, and 12 core needle biopsies obtained at the time of diagnosis were 13 (4%), 274 (77%), and 65 (18%), respectively. A total of 140 patients (40%), 139 patients (39%), 74 patients (21%), and 1 patient (0%), respectively, presented with NCCN very low-risk, who received EBRT before brachytherapy, the numbers of patients with a PSA level 10 ng/mL, 50% positive biopsy cores, and radiographic extracapsular extension were 12, 24, and 34, respectively. A total of 56 patients had at least 1 of these features. One patient received neoadjuvant ADT because of having received prior radiotherapy for rectal cancer.
Clinical Outcomes
The median follow-up was 8 A total of 44 patients (12.4%; 9 with very low-risk, 18 with low-risk, and 17 with intermediate-risk [11 with FIR and 6 with UIR] disease) developed biopsy-proven local disease recurrence at a median of 7.6 years (IQR, 3.9-11.2 years). Biopsies were performed by MR (18 patients), ultrasound (24 patients), or MR-ultrasound fusion (2 patients). Nineteen patients (43% of those with a local disease recurrence) had pathologic evidence of disease outside of the implanted peripheral zone (ie, central or transitional zone). The 10-year local disease recurrence estimates for patients with very low-risk, low-risk, and intermediate-risk disease were 6.5% (95% CI, 2.6%-12.9%), 15.9% (95% CI, 8.9%-24.8%), and 22.5% (95% CI, 11.6%-35.6%), respectively (Fig. 1C) . Initial salvage therapies included brachytherapy alone (17 patients), neoadjuvant/concurrent ADT with brachytherapy (3 patients), prostatectomy alone (2 patients), neoadjuvant ADT followed by salvage prostatectomy (1 patient), and ADT alone (10 patients, including 3 who developed distant metastases within 1 year of local disease recurrence). Eleven patients did not receive any salvage therapy, with a median PSA level of 14.4 ng/mL (IQR, 8.7-17.4 ng/mL) at the time of last follow-up. It is interesting to note that 39 patients who met the standard definition of biochemical disease recurrence did not undergo any additional imaging or biopsies, and 4 developed distant metastases.
A total of 33 patients (9.3%; 3 with very low-risk, 17 with low-risk, and 13 with intermediate-risk [8 with Figure 1 . Kaplan-Meier curves of (A) biochemical progression-free survival (nadir plus 2) and (B) modified biochemical progression-free survival (nadir plus 2 with prostate-specific antigen velocity > 0.75 ng/mL/year). Cumulative incidence curves of (C) biopsy-proven local disease recurrence, (D) androgen deprivation therapy, (E) metastasis, and (F) prostate cancer-specific mortality. All curves were stratified by National Comprehensive Cancer Network risk categories. P values compare curves according to National Comprehensive Cancer Network risk group.
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Cancer September 1, 2018 (Fig. 1D ). A total of 22 patients (6.2%; 2 with very low-risk, 13 with low-risk, and 7 with intermediate-risk [4 with FIR and 3 with UIR] disease) developed distant metastasis at a median of 11.0 years (IQR, 6.9-13.9 years). The 10-year metastasis estimates for patients with very low-risk, low-risk, and intermediate-risk disease were 0.8% (95% CI, 0.1%-4.4%), 3.5% (95% CI, 0.9%-9.1%), and 8.2% (95% CI, 2.5%-18.5%), respectively (Fig. 1E ). Fourteen patients (1 with very low-risk, 10 with low-risk, and 3 with intermediate-risk disease) experienced events > 10 years from therapy. The corresponding 12-year estimates were 0.8% (95% CI, 0.1%-4.4%), 8.7% (95% CI, 3.4%-17.2%), and 15.7% (95% CI, 5.7%-30.2%), respectively. The differences in survival curves were statistically significant (P<.01) (Fig. 1E) . The incidence of metastatic disease per 1000 person-years was 7.2 (95% CI, 4.6-10.6).
Six patients (1.7%; 1 with very low-risk, 2 with lowrisk, and 3 with intermediate-risk [2 with FIR and 1 with UIR] disease) died of prostate cancer at a median of 9.9 years (IQR, 7.2-11.0 years). Four patients (2 with lowrisk and 2 with intermediate-risk disease) had developed local disease recurrences that were salvaged with brachytherapy (2 patients) and ADT (2 patients). The 10-year estimates of PCSM for patients with very low-risk, lowrisk, and intermediate-risk disease were 0, 1.4% (95% CI, 0.1%-6.8%), and 4.4% (95% CI, 0.8%-13.4%), respectively. The corresponding 12-year estimates were 1.6% (95% CI, 0.1%-7.6%), 1.4% (95% CI, 0.1%-6.8%), and 8.2% (95% CI, 1.9%-20.7%), respectively. The differences in survival curves were not statistically significant (P 5 .11) (Fig. 1F) . The incidence of PCSM per 1000 person-years was 1.9 (95% CI, 0.7-3.9).
To facilitate comparisons with historical data, the 10-year biochemical progression-free survival, 10-year modified biochemical progression-free survival, 10-year local disease recurrence, 10-year ADT, 10-year and 12-year metastasis, and 10-year and 12-year PCSM estimates for the combined low-risk (very low-risk plus low-risk disease) cohort were 65.4% (95% CI, 58.8%-72.8%), 78.7% (95% CI, 73.5%-84.3%), 11.0% (95% CI, 6.9%-16.2%), 5.5% (95% CI, 2.8%-9.5%), 2.1% (95% CI, 0.7%-5.0%) and 4.6% (95% CI, 2.0%-8.9%), and 0.7% (95% CI, 0.1%-3.3%) and 1.5% (95% CI, 0.2%-4.8%), respectively.
Factors Associated With Metastasis
As shown in Table 2 
DISCUSSION
The contemporary management of patients with favorable-risk prostate cancer remains controversial. Given the concern regarding overtreatment in the PSA screening era, 19 investigators have devised alternative management strategies. Active surveillance is one such strategy, in which low-risk patients undergo serial PSA checks and prostate biopsies to detect disease progression. Long-term results from prospective protocols have shown that approximately one-half of patients with favorablerisk disease can avoid treatment at >10 years from diagnosis. 20, 21 Partial gland therapies represent alternative treatment strategies for the treatment of focal cancer while minimizing toxicity. These therapies include brachytherapy 16, 22 ; cryotherapy 23 ; laser; photodynamic; interstitial electroporation; and either ultrasound-guided or MRguided high-intensity focused ultrasound. 24 The volume to be ablated can range from hemi-gland to peripheral zone to individual index lesions. A recent systemic review demonstrated that focal or partial therapies were well tolerated, with low estimates of serious adverse events (range, 0%-10.6%). However, median follow-up times among the 37 included articles were relatively short (range, 4-61 months), and to our knowledge long-term oncologic effectiveness remains undefined. 25 In the current study, we have presented long-term oncologic outcomes (median follow-up of 8.6 years) of what to the best of our knowledge is the largest singleinstitutional series to date of partial therapy (ie, less than whole-gland treatment) in the definitive setting using MRI-guided prostate brachytherapy to the peripheral zone. Although we previously reported very low rates of radiation cystitis based on this approach, 26 a subsequent publication with a median 5-year follow-up concluded that this approach did not appear to be adequate for men with intermediate-risk disease based on poor biochemical disease control. 16 Our updated results herein corroborated these findings, with 10-year estimates of biochemical progression-free survival (65.4% for combined low risk and 28.4% for intermediate risk) and modified biochemical progression-free survival (78.7% for combined low risk and 49.7% for intermediate risk) that were inferior to long-term rates associated with whole-gland prostate brachytherapy from series with adequate postimplantation quality assessment. [2] [3] [4] [5] In fact, the reported biochemical control rates from these series were more comparable to our reported 10-year rates of biopsyproven local disease recurrences (11.0% for combined low risk and 22.5% for intermediate risk). We attribute the high PSA failure rates, especially in patients with intermediate-risk disease, to multiple factors, including undersampled (eg, 6 core needle biopsies) and underimaged (eg, nonmultiparametric MRI) prostates, in which the anterior gland did not receive an adequate dose. In addition, patients with concerning risk factors (eg, UIR disease or radiographic extracapsular extension) did not receive ADT.
The median time to metastasis was 11.0 years, and NCCN risk category was the only factor found on multivariate analysis to be significantly associated with time to metastasis. Although the 10-year rates of metastasis for combined low-risk (2.1%) and intermediate-risk (8.2%) disease were comparable to respective rates of 5.4% (low risk) and 12% (low-intermediate risk) from a recent whole-gland brachytherapy monotherapy series with or without ADT by Kittel et al, 5 our 12-year metastasis rates (4.6% for low risk and 15.7% for intermediate risk) were inferior to respective rates (2% and 5%) from another institutional series by Marshall et al. 4 In this series, patients with low-risk disease were treated with brachytherapy monotherapy, and those with intermediate-risk disease were treated with ADT plus brachytherapy with or without EBRT. Furthermore, despite comparable 12-year PCSM rates for combined low-risk disease (1.5% vs 3%), our rates for intermediate-risk disease were noticeably higher (8.2% vs 2%). The 12-year PCSM rates in the current study also were greater than the rates of 0.2% (low risk) and 0.7% (intermediate risk) reported from another series of patients treated with brachytherapy with or without ADT and/or EBRT reported by Taira et al. 3 Both patients with FIR and UIR disease remained at risk of biochemical disease recurrence (20 with FIR and 10 with UIR disease), biopsy-proven local disease recurrence (11 with FIR and 6 with UIR disease), metastasis (4 with FIR and 3 with UIR disease), and PCSM (2 with FIR and 1 with UIR disease).
With respect to other management strategies, approximately 40% of the current study population had NCCN very low-risk disease. For this cohort, the 10-year rates of metastasis (0.8%) and PCSM (0%) were comparable to rates from prospective series of active surveillance. 20, 21 Among all patients, the incidence of metastatic disease (7.2 [95% CI, 4.6-10.6] per 1000 person-years) was similar to that of the active monitoring arm on the Prostate Testing for Cancer and Treatment (ProtecT) trial (6.3 [95% CI, 4.5-8.8] per 1000 person-years), but more than double the incidences for the surgery (2.4 [95% CI, 1.4-4.2]) and EBRT (3.0 [95% CI, 1.9-4.9]) arms. It is interesting to note that the ProtecT trial had a population that was at higher risk than the population herein, with greater percentages of patients with Gleason grade 7 to 8 tumors (22% vs 12%) and clinical T2 disease (25% vs 0%). 27 
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Cancer September 1, 2018 Outcomes of Partial Prostate Brachytherapy/King et al Nearly one-half (19 of 44 patients) of the patients with a biopsy-proven local disease recurrence had pathologic evidence of disease outside of the implanted peripheral zone. This result was concordant with a prior analysis in which 2 experienced radiologists blinded to clinical data evaluated MRI images for 10 patients with biopsyproven disease recurrences, and estimated that approximately 50% of recurrences occurred within the nontargeted central zone. 28 One possibility for this is that there was no disease within the anterior transitional zone initially, but the peripheral zone was not completely implanted. Although we do not have dosimetric data for the entire cohort in the current study, we did previously report that, in a subset of 43 patients, the median percentage of the peripheral zone receiving the prescription dose was 96% (range, 89%-99%) on intraoperative assessment. 15 A second consideration is that disease within the anterior transitional zone was not detected with older 1.5-Tesla or 0.5-Tesla MRI techniques. A prior study of 1312 whole-mount prostatectomy specimens reported a 15% rate of anterior-predominant disease, with approximately one-half of specimens demonstrating transitional zone involvement. 11 Modern imaging techniques, such as 3.0-Tesla multiparametric MRI using diffusion-weighted and multiparametric sequences, interpreted according to the PI-RADS (version 2.0) 14 followed by MR-targeted biopsy could have detected and localized, with greater accuracy, clinically significant (tumors with a Gleason grade of 4 and/or a volume >0.5 cm 3 ) disease within the anterior transitional zone. A recent meta-analysis focused on the important role of multiparametric MRI for the detection of clinically significant prostate cancer and pooled data from 12 articles demonstrated a negative predictive value of 63% to 89%. 29 In addition, the Prostate MRI Imaging Study (PROMIS) trial demonstrated multiparametric MRI to be highly sensitive for the detection of clinically significant disease (93%) when compared with saturation biopsy mapping. 30 However, a recent comparative analysis of multiparametric 3.0-Tesla MRI against wholemount prostatectomy specimens revealed a poor overall tumor detection sensitivity of 47%. Despite the 80% sensitivity for index lesions, the detection of nonindex lesions, even with high-grade disease, was suboptimal at 21%. 31 A third consideration is that there was an inadequate dosimetric margin for dominant lesions bordering the transitional zone.
A key strength of the current study is the relatively long follow-up in a large cohort of patients who received partial therapy using a well-established treatment modality (ie, brachytherapy) 7 with MR guidance. Limitations include its retrospective nature; the lack of a comparator arm; the use of outdated MR technologies for patient selection, treatment, and the early follow-up period; potential pathologic undersampling (with only 18% of patients receiving 12 pretreatment core needle biopsies); the lack of postimplantation dosimetry for all patients; selection bias with respect to EBRT, as well as heterogeneity in the workup of biochemical disease recurrences. The long-term outcomes of MRI-guided partial prostate brachytherapy are significant in the current era of active surveillance 20, 21 and partial prostate therapies, 25 especially with metastasis as a primary endpoint. 32 Although the current analysis was performed without the identification of dominant lesions within the prostate or an appropriate dosimetric margin for disease adjacent to the transitional zone, the results suggest that partial/focal gland approaches, even with advanced multiparametric MRI technologies, risk a serious decline in efficacy. Unlike active surveillance, partial therapies may preclude definitive therapy for a subset of patients with progressive disease (only 23 of 44 patients with local disease recurrence underwent a salvage procedure in the current series). Given the decreased reliability of PSA as a marker for biochemical disease progression for partial treatments with a residual PSA-producing gland, 16, 33 patients receiving partial therapies should be enrolled on well-defined surveillance protocols after treatment. Furthermore, due to the higher estimates of metastasis and PCSM for patients with intermediate-risk disease, partial therapies may not be appropriate for this cohort, including those with FIR disease, because these patients remain at risk of these endpoints. However, this awaits validation from ongoing prospective trials examining various forms of focal/partial therapy using current imaging technology.
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